Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Dec 6, 2021 (5 years ago)

Mitomycin-C

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Mitomycin-C, 40mg/40mL (1mg/mL), 40 mL per syringe, Single Dose Syringe for Intravesical Use, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT 05446, NDC 05446-1416-01

Affected NDC 5446-1416-01

Compare with the code on your package — it is the most precise check available.

Drug: Mitomycin

Recalling firm
Edge Pharma, LLC
NDC code
05446-1416-01
Origin
VT, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0407-2022 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Mitomycin recalls

See all
Class II · Moderate risk

Mitomycin 0.4mg/Ml

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

Terminated Sterility / contamination Pharmacy Innovations D-0224-2023
Class II · Moderate risk

Mitomycin 0.2mg/Ml

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

Terminated Sterility / contamination Pharmacy Innovations D-0223-2023
Class II · Moderate risk

MITOMYCIN INJECTION 0.375 mg/mL SYR

Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Ongoing Sterility / contamination Pharmacy Plus, Inc. dba Vital Care Compounder D-0039-2023

Other recalls by Edge Pharma, LLC

All 2021 recalls